Cardiovascular effects of butorphanol in halothane-anesthetized dogs.
Cardiovascular effects of butorphanol (0.2 mg/kg of body weight, IV) and responses associated with subsequent administration of naloxone (0.04 mg/kg, IV) were studied in halothane (1.2% end-tidal concentration)-anesthetized dogs. Transient, but statistically significant (P less than 0.05), decreases in heart rate, mean and diastolic arterial blood pressures, and rate-pressure product were observed after butorphanol administration. Cardiac index, stroke volume, and systemic vascular resistance did not change significantly. Except for the decrease in heart rate, changes in the values of the cardiovascular variables measured after butorphanol administration did not appear to be clinically relevant. Sixty minutes after butorphanol administration, naloxone was given. Statistically significant (P less than 0.05) increases in heart rate, arterial blood pressures, cardiac index, and rate-pressure product, along with dysrhythmias were observed. Stroke volume and systemic vascular resistance remained unchanged after administration of naloxone. Naloxone administration was associated with changes indicative of increased myocardial oxygen consumption.
Greene
S A
SA
Department of Veterinary Large Animal Medicine, Texas Veterinary Medical Center, Texas A&M University, College Station 77843.
Hartsfield
S M
SM
Tyner
C L
CL
D000769:Anesthesia, Inhalation / Q000662:veterinary*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D001831:Body Temperature / Q000187:drug effects; D002077:Butorphanol / Q000494:pharmacology*; D002302:Cardiac Output / Q000187:drug effects; D004285:Dogs / Q000502:physiology*; D004357:Drug Synergism; D005260:Female; D006221:Halothane; D006339:Heart Rate / Q000187:drug effects*; D008297:Male; D009019:Morphinans / Q000494:pharmacology*; D009270:Naloxone / Q000494:pharmacology*; D013997:Time Factors
D009019:Morphinans; D009270:Naloxone; D002077:Butorphanol; D006221:Halothane